

# Recruitment for ADCS Trials

Mary P. Sundsmo, MBA

Program Director/Administrator

UCSD ADRC

# Know the right people

- Know your ADC administrator and feel comfortable contacting him/her
- Know your clinical trial Study Coordinators
- Know the staff of your local Chapter of the Alzheimer's Association

# What Can Your ADC Administrator do for You?

- Our roles are varied but our purpose is unified
- Conduit among Cores/Programs/Projects
  - Meetings
  - Sharing knowledge
  - Direct pipeline to the Center Director
- Link to the Alzheimer's Association

# Don't Reinvent the Wheel

- Be familiar with existing resources
- Publications from ADEAR/Alz. Association
  - Unravelling the Mystery booklet + Speaker's kit
  - Progress Report
  - Aging Under the Microscope booklet
  - Many pamphlets
- NIH/Alzheimer's Association Web resources
  - <http://www.clinicaltrials.gov>
  - <http://www.seniorhealth.gov>
  - <http://www.alz.org>

# Local Chapter of the Alzheimer's Association

- Efforts of the ADCS
- Newsletters
- Referrals
  - Develop a process
  - Need to know your inclusion criteria
  - Need feedback for reinforcement

# Make a recruitment plan

- Who is your target audience?
  - Recruit through your longitudinal study?
  - Recruit from outside your Center?
- What does a person need to know to decide to participate?
- What is the face we present to the public?
- Advertising
- Community Informational Talks

# Centerfold of the UCSD Newsletter

## Clinical Trials

THERE ARE MANY NEW CLINICAL TRIALS AND RESEARCH PROTOCOLS ENROLLING AT THE ADRC

If you are interested in participating or would like more information, please contact the Study Coordinator listed with each trial.

• They can all be reached at the ADRC - (858) 622-5800

• There is no cost to participate in any of these research protocols

• The ADRC is under the direction of Leon J. Thal, M.D.

## Clinical Trials Registry

Are you interested in clinical trials but don't find one that suits you? You can now join our ADRC Registry to be placed on a list for future studies.

- PARTICIPANTS CAN BE:
- ➔ Normal Controls
  - ➔ Have a slight memory problem
  - ➔ Be diagnosed with early to moderate AD

Call the ADRC at (858) 622-5800

### CLASP Study Cholesterol Lowering Agent to Slow Progression of Alzheimer's Disease

**STUDY DIRECTOR**  
Gang Tong, M.D., Ph.D.

#### TIME INVOLVED

This study involves 8-9 visits over 20 months

#### DESCRIPTION

Statins are drugs that are used to lower cholesterol to reduce the risk of heart disease. This study will investigate the safety and effectiveness of simvastatin (Zocor) in slowing the progression of AD.

Studies in animals have shown a link between lowering cholesterol and decreased severity and risk of AD.

Participants will take a study drug for 18 months, and this drug may be simvastatin or it may be an inactive placebo.

All participants must be accompanied by someone who can answer questions about them and who can make sure they are taking the study drug.

If you or a family member have AD, and are not currently taking a cholesterol drug, you may be eligible to participate.

#### CONTACT

Susan Johnson, G.N.P., at (858) 622-5800 and ask for the "Statin Study"

### Huperzine A

**STUDY DIRECTOR**  
Jody Corey-Bloom, M.D., Ph.D.

#### TIME INVOLVED

Study participation will be 24 weeks

#### DESCRIPTION

This study is to determine whether huperzine A is beneficial in the treatment of mild to moderate Alzheimer's disease. Huperzine A is a natural cholinesterase inhibitor, derived from the Chinese herb huperzia serrata, used in China to treat AD. Individuals 55 years of age or older who are not currently taking cholinesterase inhibitors and have mild to moderate Alzheimer's disease are eligible for screening. Treatment with memantine (Namenda) and vitamin E is allowed.

Two-thirds of participants will be randomly assigned to receive huperzine A throughout the study; one-third will receive placebo for the first 18 weeks. An open-label extension study providing huperzine A to all participants for at least 6 months is anticipated.

There will be no payment for participation in this study; however, all tests, examinations, and medical care required as part of the study will be provided.

#### CONTACT

Karen Wetzel, M.P.A.S., PA-C, at (858) 622-5823 and ask for the "Huperzine A Study"

### VALID Valproate in Dementia

**STUDY DIRECTOR**  
Jody Corey-Bloom, M.D., Ph.D.

#### TIME INVOLVED

Study participation will be 26 months

#### DESCRIPTION

This study is to find out whether valproate is beneficial in delaying agitation and/or psychosis in patients with mild to moderate AD. Valproate is FDA approved for several indications, but not the treatment of agitation and/or psychosis in AD. Its use in this study is considered experimental.

VALID seeks participants who:

- Are age 55-90
- Have mild to moderate AD
- Have not experienced agitation or psychosis since onset
- Treatment with Aripcept, Reminyl, Exelon, Namenda and/or vitamin E is allowed

Participants will be randomly assigned to receive Valproate for 24 of 26 months with placebo for 2 of the 26 months, or placebo for all 26 months. There will be no payment for participation in this study; however, all tests, examinations, and medical care required as part of the study will be provided at no cost.

#### CONTACT

Karen Wetzel, M.P.A.S., PA-C, at (858) 622-5823 and ask for the "VALID Study"

### ONO-2506

**STUDY DIRECTOR**  
Jody Corey-Bloom, M.D., Ph.D.

#### DESCRIPTION

This is a study to find out whether an experimental drug, ONO-2506, is beneficial in the treatment of patients with mild to moderate AD. This study is sponsored by ONO Pharma, Inc.

We are seeking participants who:

- Are age 50-90
- Have mild to moderate AD
- Are not taking galantamine (Reminyl), tacrine (Cognex), or memantine (Namenda)
- Treatment with donepezil (Aripcept), rivastigmine (Exelon), and/or vitamin E is allowed

Participants will be randomly assigned to receive one of two doses of the experimental drug ONO-2506 or a placebo.

#### COMPENSATION

There will be no payment for participation in this study; however, all tests, examinations, and medical care required as part of the study will be provided at no cost.

#### CONTACT

Karen Wetzel, M.P.A.S., PA-C, at (858) 622-5823 and ask for the "ONO-2506 Study"

### SRA-333

**STUDY DIRECTOR**  
Jody Corey-Bloom, M.D., Ph.D.

#### DESCRIPTION

This is a study sponsored by Wyeth Pharmaceuticals to find out more about the safety, tolerability and effectiveness of an experimental drug, SRA-333, in patients with mild to moderate AD. This drug is considered experimental because it has not been approved by the Food and Drug Administration (FDA).

We are seeking participants who:

- Are age 50 and older
- Have mild to moderate AD
- Are not taking medications for treatment of their memory

#### COMPENSATION

There will be no payment for participation in this study; however, all tests, examinations, and medical care required as part of the study will be provided at no cost.

#### CONTACT

Karen Wetzel, M.P.A.S., PA-C, at (858) 622-5823 and ask for the "SRA-333 Study"

### Cerebral Spinal Fluid (CSF) Studies

**STUDY DIRECTOR**  
Douglas Galasko, M.D.

#### DESCRIPTION

We are currently looking for participants for a group of CSF studies, some of which involve using CSF (Cerebral Spinal Fluid) to monitor a response to an experimental procedure and others involve looking for novel diagnostic biomarkers for AD.

Both normal controls and early to moderate AD participants are needed.

These studies will involve lumbar puncture for the withdrawal of cerebrospinal fluid.

#### COMPENSATION

You will be compensated \$200.00 for your participation.

#### CONTACT

Helen Vanderswag, RNC, BSN and ask for the "CSF Study"

# Think Outside the Box

- Do you have a flow-through clinic to provide a stream of new potential subjects?
  - ADCS Blue-sheet (Page 11)
- Ideas for finding potential research subjects
  - A primary care provider system with no research program of its own
- **There is no one right answer!**



# Did You Know?

- You can use any article from ADEAR's 'Connections' in your Center newsletter or part of recruitment materials.
- ADCS has provided funds for recruitment in many recent studies. Have you used yours?

# ADCS Recruitment & Retention Booklet

- Advertisements p.5-6
- What is Their Secret? p.9

# Recruitment is a Team Project

- Anyone who has contact with families is a recruiter
- We need to sell clinical research
- Need to be familiar with all studies
  - Clinical Trials
  - Imaging Studies – ADNI is coming
  - Genetics Studies – Genetics Initiative
  - Other studies